Compare CAPR & INSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CAPR | INSP |
|---|---|---|
| Founded | 2005 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.6B |
| IPO Year | 2011 | 2018 |
| Metric | CAPR | INSP |
|---|---|---|
| Price | $30.24 | $41.71 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 16 |
| Target Price | $44.63 | ★ $94.00 |
| AVG Volume (30 Days) | 968.6K | ★ 1.0M |
| Earning Date | 05-12-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 179.43 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $82,050,000.00 |
| Revenue This Year | N/A | $8.02 |
| Revenue Next Year | $3.31 | $8.11 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 62.18 |
| 52 Week Low | $4.30 | $42.84 |
| 52 Week High | $40.37 | $152.36 |
| Indicator | CAPR | INSP |
|---|---|---|
| Relative Strength Index (RSI) | 42.17 | 28.19 |
| Support Level | $26.06 | N/A |
| Resistance Level | $30.06 | $59.40 |
| Average True Range (ATR) | 2.12 | 2.59 |
| MACD | -0.53 | -1.16 |
| Stochastic Oscillator | 19.86 | 0.58 |
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
Inspire Medical Systems Inc operates as a medical technology company. It focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA). It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. The firm has operating footprints in the United States and All other countries wherein, it generates a majority of its revenue from the United States. Its segment revenues are derived from the sales of its product, the Inspire system, to hospitals and ambulatory surgery centers in the U.S. and in selected countries in Europe and the Asia Pacific region.